NCT04838613View on ClinicalTrials.gov

Study of Diagnostic Performance of [18F]CTT1057 in BCR

PHASE3CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

November 23, 2023

Study Completion Date

November 23, 2023

Conditions
Prostatic NeoplasmsProstate CancerRecurrence
Interventions
DRUG

[18F]CTT1057

Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan

DRUG

[68Ga]Ga-PSMA-11

Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan

Trial Locations (13)

1211

Novartis Investigative Site, Geneva

13273

Novartis Investigative Site, Marseille

13885

Novartis Investigative Site, Marseille

30029

Novartis Investigative Site, Nîmes

31059

Novartis Investigative Site, Toulouse

42270

Novartis Investigative Site, Saint-Priest-en-Jarez

46026

Novartis Investigative Site, Valencia

69495

Novartis Investigative Site, Pierre-Bénite

95816

Explorer Molecular Imaging center, Sacramento

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

08041

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY